- Molecular NameSalmeterol
- SynonymSalmeterolum [Latin]
- Weight415.574
- Drugbank_IDDB00938
- ACS_NO89365-50-4
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)3.8
- pkaN/A
- LogD (pH=7, predicted)2.09
- Solubility (experiment)Sparingly soluble
- LogS (predicted, ACD/Labs)(ph=7)-0.92
- LogSw (predicted, AB/LogsW2.0)0.35
- Sw (mg/ml) (predicted, ACD/Labs)0.57
- No.of HBond Donors4
- No.of HBond Acceptors5
- No.of Rotatable Bonds16
- TPSA81.95
- StatusFDA approved
- AdministrationInhalation
- PharmacologyA long-acting beta2-adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently available as a metered-dose inhaler (MDI) or a proprietary "disk-styled" inhaler that releases a powdered form of the drug.
- Absorption_valueN/A
- Absorption (description)Because of the small therapeutic dose, systemic levels of salmeterol are low or undetectable after inhalation of recommended doses.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding96.0
- Volume of distribution (VD)Steady state, 7.26 L
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic CYP3A4
- Half life5.5 h for salmeterol; 15 days (healthy individuals); 30 days (patients with renal impairment) for xinafoic acid.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include angina (chest pain), dizziness, dry mouth, fatigue, flu-like symptoms, headache, heart irregularities, high or low blood pressure, high blood sugar, insomnia, muscle cramps, nausea, nervousness, rapid heartbeat, seizures, and tremor. By the oral route, no deaths occurred in rats at 1,000 mg/kg (approximately 81,000 times the maximum recommended daily inhalation dose in adults and approximately 38,000 times the maximum recommended daily inhalation dose in children on a mg/m2 basis).
- LD50 (rat)N/A
- LD50 (mouse)N/A